血浆BNP测定在老年性呼吸困难鉴别诊断中的价值

目的检测老年呼吸困难患者血浆BNP水平并探讨其临床应用价值。方法选择有呼吸困难的老年患者共82例，用ELISA方法快速测定BNP水平。结果对诊断心源性呼吸困难患者36例和肺源性呼吸困难患者46例，进行回顾性分析，其血浆BNP水平分别为（628．32±420．22）pg/ml和（146．38±86．26）pg／ml。心源性呼吸困难与肺源性呼吸困难患者比较，其血浆BNP水平有非常显著差异（P〈0．01）。结论血浆BNP测定，对老年性呼吸困难的快速鉴别诊断具有重要的价值。     

脑钠肽对呼吸困难的诊断价值

目的探讨血清脑钠肽（BNP）检测水平在呼吸困难鉴别诊断中的价值。方法选取在我科住院并且经过各种检查及治疗已经明确诊断的心源性呼吸困难患者52例和肺源性呼吸困难患者98例,分成两组并比较两组患者在呼吸困难发作时血清脑钠肽（BNP）的检测水平。结果心源性呼吸困难组患者的BNP值为（1235pg/ml±938pg／ml）、肺源性呼吸困难组患者的BNP值为（64pg／ml±48pg／ml）,两组BNP值水平比较有显著性差异（P〈0．01）。结论血清脑钠肽（BNP）检测水平对于心源性与肺源性呼吸困难的鉴别诊断中具有很高的价值。     

脑钠素在急诊呼吸困难鉴别诊断中的应用

目的研究血浆脑钠素(BNP)水平对急诊患者呼吸困难鉴别诊断意义。方法对我院急诊科呼吸困难患者,检测血浆BNP含量,并进行超声心动图检查,比较心源性和肺源性呼吸困难患者血浆BNP水平的差异。结果心源性呼吸困难组和肺源性呼吸困难组血浆BNP分别为613.1±116.4 pg/mL和45.8±31.6 pg/mL(P0.01);心源性呼吸困难组血浆BNP与左室射血分数呈负相关(r=-0.54,P0.05)。结论血浆BNP对心源性呼吸困难和肺源性呼吸困难的鉴别诊断有重要意义。     

血浆B型钠尿肽测定在诊断老年急性呼吸困难中的应用

目的探讨血浆BNP测定在诊断老年性急性呼吸困难中的应用。方法选择呼吸困难的老年患者共106例,选择正常对照组50例,用荧光免疫法快速测定BNP水平。结果对明确诊断的心源性呼吸困难患者51例和肺源性呼吸困难患者55例,进行回顾性分析,其血浆BNP水平分别为（843．12±432．12）pg／ml和（159．34±97．62）pg／m;对照组50例,其血浆BNP水平为（52．16±16．96）pg／ml。心源性呼吸困难患者与对照组及肺源性呼吸困难患者比较,其血浆BNP水平均有显著差异（P〈0．01）,肺源性呼吸困难患者与对照组比较,血浆BNP水平相对升高,有统计学差异（P〈0．05）。结论血浆BNP水平测定对老年性呼吸困难的快速鉴别诊断具有较重要的意义。     

急性呼吸困难患者血浆脑利钠肽检测的临床价值

目的探讨血浆脑利钠肽（BNP）检测对心源性呼吸困难和肺源性呼吸困难的诊断和鉴别价值。方法对住院的急性呼吸困难患者，用免疫发光定量检测血浆BNP含量，随后进行超声心动图等常规检查，比较心源性呼吸困难和肺源性呼吸困难患者血浆BNP水平的差异。结果心源性呼吸困难组、肺源性呼吸困难组血浆BNP分别为（604．78±137．70）ng/L和（43．56±32．73）ng／L，差异有统计学意义（P〈0．01）。心源性呼吸困难组血浆BNP与左室射血分数呈负相关（r=-0．53，P〈0．01），与左室舒张末期内径呈正相关（r=0．56，P〈0．01）。结论血浆BNP对心源性呼吸困难和肺源性呼吸困难的诊断和鉴别诊断有重要意义。     

BNP和NT-proBNP对呼吸困难的鉴别诊断意义

目的:探讨脑钠肽(BNP)和N末端脑钠肽前体(NT-proBNP)的含量变化对呼吸困难患者的鉴别诊断价值。方法:选择入院时呼吸困难患者150例,分为心源性呼吸困难组(心源性组,51例),肺源性呼吸困难组(肺源性组,47例)和肺源性呼吸困难加心源性呼吸困难组(心肺源性组,52例)。另选择正常体检者40例作为正常对照组。观察比较各组治疗前后BNP和NT-proBNP的含量。结果:治疗前,与正常对照组比较,心源性组,心肺源性组和肺源性组的血浆BNP和NT-proBNP含量均显著升高,且心源性组的显著高于肺源性组和心肺源性组,心肺源性组的显著高于肺源性组的,P均0.01;治疗前心源性组,心肺源性组,肺源性组的NT-proBNP含量依次为[(3356.6±321.2)pg/ml比(3156.9±239.8)pg/ml比(2563.7±234.20)pg/ml],组间比较P均0.01;出院1周后,3组的血浆BNP和NT-proBNP含量均较治疗前显著降低,仍是心源性组的BNP含量最高,肺源性组的最低,心肺源性组的居中,组间比较,P均0.01。结论:血浆BNP和NT-proBNP含量有助于鉴别诊断呼吸困难是否属于心源性或肺源性疾病。     

血气分析、呼气峰流速联合血浆脑利钠肽检测在呼吸困难鉴别诊断中的价值

目的探讨血气分析、呼气峰流速(PEF)联合血浆脑利钠肽(BNP)检测鉴别心源性与肺源性呼吸困难的价值。方法选择呼吸困难患者175例,其中肺源性呼吸困难患者97例、心源性呼吸困难患者78例。采用化学发光法测定其血浆BNP水平,并对BNP水平在100～500 pg/mL患者行血气分析和呼气峰流速检测。结果心源性呼吸困难患者血浆BNP水平明显高于肺源性呼吸困难患者(P<0.01)。BNP水平在100～500 pg/mL时,呼吸困难发生率为60.29%,与BNP<100 pg/mL(15.58%)及BNP>500 pg/mL(83.33%)比较均有统计学意义(P均<0.01)。BNP水平在100～500 pg/mL时,心源性、肺源性呼吸困难患者的PaO2、PaCO2、P(A-a)O2和PEF水平比较有统计学意义(P均<0.01)。结论特定BNP水平联合血气分析、呼气峰流速检测能更快速、简便地鉴别肺源性、心源性呼吸困难。     

老年急性呼吸困难患者脑利钠肽测定结果分析

目的 探讨老年急性呼吸困难患者血浆脑利钠肽(BNP)水平对临床诊断的意义及时心功能不全的诊断价值.方法 选择老年(>65岁)急性呼吸困难患者95例,其中心源性呼吸困难患者73例,肺源性呼吸困难患者22例.应用快速床旁试验方法测定血浆BNP水平,确定血浆BNP界值.结果 心功能不全所致的急性呼吸困难患者血浆BNP水平明显升高,与肺源性呼吸困难患者比较有统计学意义(P<0.05).血浆BNP诊断界值在150 pg/mL时其特异性及敏感性均达85%左右,曲线下面积(AUC)为0.869.心源性呼吸困难组合并肾功能异常患者,其诊断界值在225 pg/mL.结论 血浆BNP对于老年急性心源性呼吸困难患者有诊断价值,其诊断界值为150 pg/mL.     

NT-proBNP鉴别诊断陈旧性心肌梗死与慢性阻塞性肺病导致呼吸困难的研究

目的探讨N末端B型利钠肽原(NT-proBNP)在陈旧性心肌梗死导致的心源性呼吸困难与慢性阻塞性肺病(COPD)导致肺源性呼吸困难鉴别诊断中的价值。方法选取2011年10月—2012年6月我院收治的186例患者,分为心源性呼吸困难组(66例)、肺源性呼吸困难组(56例)、肺源性呼吸困难并发冠心病组(64例)。采用电化学发光免疫测定技术检测患者血浆中NT-proBNP的水平。结果心源性呼吸困难组、肺源性呼吸困难组与肺源性呼吸困难并发冠心病组血浆中的NT-proBNP水平分别为1 324.4 pg/mL±436.5 pg/mL、136.3 pg/mL±59.5 pg/mL、326.7 pg/mL±129.7 pg/mL,心源性呼吸困难组与肺源性呼吸困难组、肺源性呼吸困难并发冠心病组间差异有统计学意义(P0.05)。结论血浆NT-proBNP水平检测有助于快速准确地诊断陈旧性心肌梗死导致的心源性呼吸困难和慢性阻塞性肺病导致肺源性呼吸困难。     

N末端脑钠肽在心源性与肺源性呼吸困难诊断中的应用价值

目的探讨N末端脑钠肽（NT-proBNP）在心源性与肺源性呼吸困难诊断及鉴别诊断中的应用价值。方法根据临床诊断分心源性呼吸困难组（543例）与肺源性呼吸困难组（484例）。采用双向侧流免疫法测定两组患者血浆NT-proBNP水平;对比分析心源性呼吸困难组不同病因、不同心功能亚组间血浆NT-proBNP水平;肺源性呼吸困难组不同肺功能亚组间血浆NT-proBNP水平。结果心源性呼吸困难组血浆NT-proBNP水平（5163 pg/ml）显著高于肺源性呼吸困难组（496pg/ml）,P〈O.OO1;在心源性呼吸困难患者中,病因不同其血浆的NT-proBNP水平升高不同（3905.5-9379 pg/ml）,P=0.001;有并发症患者NT-proBNP水平（5615.4 pg/ml）显著高于无并发症患者（4459.2 pg/ml）,P〈0.05,且血浆NT-proBNP水平与心功能NYHA分级呈正相关（r=0.2826,p〈0.001）,与左室射血分数呈负相关（r=-0.3145,p〈0.001）。在肺源性呼吸困难患者中,有呼吸衰竭患者血浆NT-proBNP水平（2847.67pg/ml）明显高于无呼吸衰竭患者（373.96pg/ml）,p〈0.001;合并左心功能不全患者血浆NT-proBNP水平（2265pg/ml）明显高于无呼吸衰竭的患者（373.96pg/ml）,p〈0.001。结论 NTproBNP可作为鉴别心源性及肺源性呼吸困难的特异性指标;心源性呼吸困难病因中扩张型心肌病患者血浆NT-proBNP水平升高最明显;血浆NT-proBNP水平可作为心源性呼吸困难患者病情预后评估指标;肺源性呼吸困难患者血浆NT-proBNP水平异常升高提示合并有呼吸衰竭。     

Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea.

OBJECTIVES: Since B-type natriuretic peptide (BNP) is secreted by the left ventricle (LV) in response to volume elevated LV pressure, we sought to assess whether a rapid assay for BNP levels could differentiate cardiac from pulmonary causes of dyspnea. BACKGROUND: Differentiating congestive heart failure (CHF) from pulmonary causes of dyspnea is very important for patients presenting to the emergency department (ED) with acute dyspnea. METHODS: B-natriuretic peptide levels were obtained in 321 patients presenting to the ED with acute dyspnea. Physicians were blinded to BNP levels and asked to give their probability of the patient having CHF and their final diagnosis. Two independent cardiologists were blinded to BNP levels and asked to review the data and evaluate which patients presented with heart failure. Patients with right heart failure from cor pulmonale were classified as having CHF. RESULTS: Patients with CHF (n = 134) had BNP levels of 758.5 +/- 798 pg/ml, significantly higher than the group of patients with a final diagnosis of pulmonary disease (n = 85) whose BNP was 61 +/- 10 pg/ml. The area under the receiver operating curve, which plots sensitivity versus specificity for BNP levels in separating cardiac from pulmonary disease, was 0.96 (p < 0.001). A breakdown of patients with pulmonary disease revealed: chronic obstructive pulmonary disease (COPD): 54 +/- 71 pg/ml (n = 42); asthma: 27 +/- 40 pg/ml (n = 11); acute bronchitis: 44 +/- 112 pg/ml (n = 14); pneumonia: 55 +/- 76 pg/ml (n = 8); tuberculosis: 93 +/- 54 pg/ml (n = 2); lung cancer: 120 +/- 120 pg/ml (n = 4); and acute pulmonary embolism: 207 +/- 272 pg/ml (n = 3). In patients with a history of lung disease but whose current complaint of dyspnea was seen as due to CHF, BNP levels were 731 +/- 764 pg/ml (n = 54). The group with a history of CHF but with a current COPD diagnosis had a BNP of 47 +/- 23 pg/ml (n = 11). CONCLUSIONS: Rapid testing of BNP in the ED should help differentiate pulmonary from cardiac etiologies of dyspnea.     

Accuracy of Nurse-Performed Lung Ultrasound in Patients With Acute Dyspnea: A Prospective Observational Study

In clinical practice lung ultrasound (LUS) is becoming an easy and reliable noninvasive tool for the evaluation of dyspnea. The aim of this study was to assess the accuracy of nurse-performed LUS, in particular, in the diagnosis of acute cardiogenic pulmonary congestion.We prospectively evaluated all the consecutive patients admitted for dyspnea in our Medicine Department between April and July 2014. At admission, serum brain natriuretic peptide (BNP) levels and LUS was performed by trained nurses blinded to clinical and laboratory data. The accuracy of nurse-performed LUS alone and combined with BNP for the diagnosis of acute cardiogenic dyspnea was calculated.Two hundred twenty-six patients (41.6% men, mean age 78.7 ± 12.7 years) were included in the study. Nurse-performed LUS alone had a sensitivity of 95.3% (95% CI: 92.6–98.1%), a specificity of 88.2% (95% CI: 84.0–92.4%), a positive predictive value of 87.9% (95% CI: 83.7–92.2%) and a negative predictive value of 95.5% (95% CI: 92.7–98.2%). The combination of nurse-performed LUS with BNP level (cut-off 400 pg/mL) resulted in a higher sensitivity (98.9%, 95% CI: 97.4–100%), negative predictive value (98.8%, 95% CI: 97.2–100%), and corresponding negative likelihood ratio (0.01, 95% CI: 0.0, 0.07).Nurse-performed LUS had a good accuracy in the diagnosis of acute cardiogenic dyspnea. Use of this technique in combination with BNP seems to be useful in ruling out cardiogenic dyspnea. Other studies are warranted to confirm our preliminary findings and to establish the role of this tool in other settings.     

Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea

OBJECTIVES: We compared the accuracy of B-type natriuretic peptide (BNP) assay with Doppler echocardiography for the diagnosis of decompensated congestive left-heart failure (CHF) in patients with acute dyspnea. BACKGROUND: Both BNP and Doppler echocardiography have been described as relevant diagnostic tests for heart failure. METHODS: One hundred sixty-three consecutive patients with severe dyspnea underwent BNP assay and Doppler echocardiogram on admission. The accuracy of the two methods for etiologic diagnosis was compared on the basis of the final diagnoses established by physicians who were blinded to the BNP and Doppler findings. RESULTS: The final etiologic diagnosis was CHF in 115 patients. Twenty-four patients (15%) were misdiagnosed at admission. The BNP concentration was 1,022 +/- 742 pg/ml in the CHF subgroup and 187 +/- 158 pg/ml in the other patients (p < 0.01). A BNP cutoff of 300 pg/ml correctly classified 88% of the patients (odds ratio [OR] 85 [19 to 376], p < 0.0001), but a high negative predictive value (90%) was only obtained when the cutoff was lowered to 80 pg/ml. The etiologic value of BNP was low in patients with values between 80 and 300 pg/ml (OR 1.85 [0.4 to 7.8], p = 0.4) and also in patients who were studied very soon after onset of acute dyspnea. Among the 138 patients with assessable Doppler findings, a "restrictive" mitral inflow pattern had a diagnostic accuracy for CHF of 91% (OR 482 [77 to 3,011], p < 0.0001), regardless of the BNP level. CONCLUSIONS: Bedside BNP measurement and Doppler echocardiography are both useful for establishing the cause of acute dyspnea. However, Doppler analysis of the mitral inflow pattern was more accurate, particularly in patients with intermediate BNP levels or "flash" pulmonary edema.     

B-type natriuretic peptide and extent of lesion on coronary angiography in stable coronary artery disease

OBJECTIVE: Although it is well established that plasma B-type natriuretic peptide (BNP) levels are higher in patients with acute coronary syndromes, the relationship between plasma BNP level and stable coronary artery disease is not clear. The aim of this study was to examine the relationship between plasma BNP levels and the extent of obstructive lesions on coronary angiography in stable coronary artery patients. METHODS: Plasma BNP concentrations were measured in 62 patients with a diagnosis of stable angina pectoris who had a left ventricular ejection fraction (LVEF) >or=45% on echocardiographic evaluation. Coronary angiography was performed for all patients, who were than divided into two groups according to the results of the angiography. Group I consisted of the patients who had a lesion leading to an obstruction of the lumen in any coronary artery by less than 50% or those who had normal coronary arteries. All other patients constituted group II. RESULTS: In group I (n=26), the mean plasma BNP level was 64.8+/-29.5 pg/ml. In group II (n=36), it was 99.7+/-55.4 pg/ml. BNP was significantly higher in group II (P=0.007) than group I. The BNP concentration of the patients with one-vessel disease (n=12), two-vessel disease (n=16), and three-vessel disease (n=8) were 77.9+/-34.9 pg/ml, 109.3+/-67.9 pg/ml, 113.3+/-48.1 pg/ml consecutively. In this respect, the plasma BNP was significantly higher in the groups with more extended vessel disease (P=0.02). When we compared the patients according to involvement of left anterior descending artery (LAD), BNP levels were significantly higher in this group, (116.1+/-55.8 pg/ml versus 64.1+/-30.2 pg/ml; P=0.001). CONCLUSION: Plasma levels of BNP were higher in patients who have stable coronary artery disease with preserved left ventricular systolic function. The level of increase in plasma BNP concentration was positively correlated with the extent of lesion and LAD involvement on coronary angiography.     

Prognostic value of Doppler transmitral flow patterns and cardiac natriuretic peptides in patients with chronic congestive heart failure admitted for episodes of acute decompensation

This study was designed to determine whether the restrictive filling transmitral flow velocity pattern is associated with increased plasma levels of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). It was also designed to evaluate the prognostic value of these parameters from patients with chronic congestive heart failure (CHF) admitted for episodes of acute decompensation. We performed Doppler echocardiography, measured plasma levels of ANP and BNP in 33 patients at the time of admission, and assessed the subsequent cardiac mortality for 3 months. Eleven patients (33%) had a restrictive filling pattern of deceleration time (DcT) <120 ms. Plasma ANP and BNP levels were markedly increased in all patients to 189 ± 145 pg/ml and 865 ± 559 pg/ml, respectively. Seventeen patients (52%) showed more than 700 pg/ml of plasma levels of BNP. There was a significant correlation of DcT with the plasma ANP level (r = −0.41, P = 0.017), and a better correlation of DcT with the plasma BNP level (r = −0.50, P = 0.003). The combined index of both shorter DcT (<120 ms) and higher plasma BNP levels (>700 pg/ml) was the best predictor of cardiac mortality by Cox univariate analysis (χ² = 5.87, P = 0.015). Furthermore, the sensitivity and specificity of this index for the detection of cardiac mortality were 80% and 86%, respectively. In conclusion, the combined analysis of the Doppler transmitral flow velocity pattern and measurement of the plasma BNP level is noteworthy since it is noninvasive and convenient. Moreover, it is extremely useful in predicting the prognosis for patients with chronic CHF admitted for episodes of acute decompensation. Received: December 28, 1999 / Accepted: July 14, 2000     

不同类型心力衰竭血浆B型尿钠肽浓度比较

目的 :比较不同类型心力衰竭时血浆B型尿钠肽 (BNP)浓度。方法 :对 14 9例未正规抗心力衰竭患者测定BNP并根据临床资料和超声心动图将患者分成 3种类型 :左室舒张功能不全 ,左室收缩功能不全和右室收缩功能不全 ,比较 3种类型心力衰竭时的BNP值。结果 :4 8例左室舒张功能不全BNP值 (115± 80 )pg ml,6 2例左室收缩功能不全BNP值 (5 16± 4 4 5 )pg ml,39例右室收缩功能不全BNP值 (345± 184 )pg ml,3组患者间有统计学差异 (P <0 0 5 )。结论 :不同类型心力衰竭BNP值增高程度不同 ,以左室收缩功能不全BNP值增高最为明显 ,右室收缩功能不全次之 ,左室舒张功能不全最低 ,结合其他临床资料 ,BNP浓度有助于心力衰竭类型的判断     

Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema

BACKGROUND: Brain natriuretic peptide (BNP) is useful in diagnosing congestive heart failure (CHF) in patients presenting in the emergency department with acute dyspnea. We prospectively tested the utility of BNP for discriminating ARDS vs cardiogenic pulmonary edema (CPE). METHODS: We enrolled ICU patients with acute hypoxemic respiratory failure and bilateral pulmonary infiltrates who were undergoing right-heart catheterization (RHC) to aid in diagnosis. Patients with acute coronary syndrome, end-stage renal disease, recent coronary artery bypass graft surgery, or preexisting left ventricular ejection fraction /= 1,200 pg/mL, BNP had a specificity of 92% for CPE. Higher levels of BNP were associated with a decreased odds for ARDS (odds ratio, 0.4 per log increase; p = 0.007) after adjustment for age, history of CHF, and right atrial pressure. BNP was associated with in-hospital mortality (p = 0.03) irrespective of the final diagnosis and independent of APACHE (acute physiology and chronic health evaluation) II score. CONCLUSION: In ICU patients with hypoxemic respiratory failure, BNP appears useful in excluding CPE and identifying patients with a high probability of ARDS, and was associated with mortality in patients with both ARDS and CPE. Larger studies are necessary to validate these findings.